Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcadia Biosciences (RKDA) Invested Capital (2016 - 2025)

Arcadia Biosciences filings provide 12 years of Invested Capital readings, the most recent being $4.1 million for Q4 2025.

  • On a quarterly basis, Invested Capital fell 33.47% to $4.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.1 million, a 33.47% decrease, with the full-year FY2025 number at $4.1 million, down 33.47% from a year prior.
  • Invested Capital hit $4.1 million in Q4 2025 for Arcadia Biosciences, down from $5.4 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $46.8 million in Q1 2021 to a low of $4.1 million in Q4 2025.
  • Median Invested Capital over the past 5 years was $16.1 million (2023), compared with a mean of $19.5 million.
  • Biggest five-year swings in Invested Capital: surged 282.74% in 2021 and later plummeted 60.81% in 2025.
  • Arcadia Biosciences' Invested Capital stood at $31.3 million in 2021, then tumbled by 32.99% to $20.9 million in 2022, then crashed by 39.36% to $12.7 million in 2023, then crashed by 51.01% to $6.2 million in 2024, then plummeted by 33.47% to $4.1 million in 2025.
  • The last three reported values for Invested Capital were $4.1 million (Q4 2025), $5.4 million (Q3 2025), and $4.5 million (Q2 2025) per Business Quant data.